This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bolli, P. Articles by Buhler, F. R. Search for Related Content PubMed PubMed Citation Articles by Bolli, P. Articles by Buhler, F. R.

Circulation, Vol 75, 221-228, Copyright © 1987 by American Heart Association

ARTICLES

The vasodilator potency of atrial natriuretic peptide in man

P Bolli, FB Muller, L Linder, AE Raine, TJ Resink, P Erne, W Kiowski, R Ritz and FR Buhler

The vasodilating potency of alpha-human atrial natriuretic peptide (alpha-hANP) was investigated in the forearms of 16 normotensive subjects, 22 to 48 (mean 28) years old, with the use of venous occlusion plethysmography. alpha-hANP, 0.005 to 1.5 micrograms/min/100 ml forearm volume (FAV), infused in nine dose steps into the brachial artery increased forearm blood flow (FAF; ml/min/100 ml FAV) from 2.8 +/- 0.4 (SEM) to a maximum of 9.6 +/- 1.1. Forearm vascular resistance (mean arterial pressure/FAF) decreased by 72%. The alpha-hANP dose that produced a 50% vasodilator response was 0.093 +/- 0.016 microgram/min/100 ml FAV (n = 11) and it resulted in a venous plasma concentration of ANP (pANP) of 115 +/- 7 pmol/liter (normal 2 to 80; radioreceptor assay). Intraindividually, the maximum dose of alpha-hANP induced an increase in FAF that was 60% of the maximum response to sodium nitroprusside (14.1 +/- 1.8). Combined infusions (n = 9) of maximum forearm vasodilator doses of alpha-hANP and nitroprusside increased FAF to 22.7 +/- 3.4; this additive vasodilator effect of alpha-hANP and nitroprusside is consistent with their different actions on the guanylate cyclase system. In man, the direct vasorelaxant effect of alpha-hANP occurs at concentrations within the upper normal range of pANP, suggesting a physiologic vasodilator role for alpha-hANP.

This article has been cited by other articles:

				M. Komarek, A. Bernheim, R. Schindler, R. Steden, W. Kiowski, and H. P. B.-L. Rocca Vascular Effects of Natriuretic Peptides in Healthy Men Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2004; 9(4): 263 - 270. [Abstract] [PDF]

				M. Ueno, T. Miyauchi, S. Sakai, T. Kobayashi, K. Goto, and I. Yamaguchi Effects of physiological or pathological pressure load in vivo on myocardial expression of ET-1 and receptors Am J Physiol Regulatory Integrative Comp Physiol, November 1, 1999; 277(5): R1321 - R1330. [Abstract] [Full Text] [PDF]

				A. J.H.M Houben, M. M.E Krekels, N. C Schaper, M. J.M.J Fuss-Lejeune, S. A Rodriguez, and P. W de Leeuw Microvascular effects of atrial natriuretic peptide (ANP) in man: studies during high and low salt diet Cardiovasc Res, August 1, 1998; 39(2): 442 - 450. [Abstract] [Full Text] [PDF]